EBS - Emergent Biosolutions Q4 results mixed co guides FY 2023 revenue in-line
- Emergent Biosolutions press release ( NYSE: EBS ): Q4 Non-GAAP EPS of -$0.31 misses by $0.25 .
- Revenue of $330.7M (-54.3% Y/Y) beats by $32.47M .
- Sees FY 2023 revenue of $1.10B to $1.20B. The consensus FY 2023 revenue estimate is $1.17B.
- Sees Q1 2023 revenue of $130M to $150M.
For further details see:
Emergent Biosolutions Q4 results mixed, co guides FY 2023 revenue in-line